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Objective: There are limited contemporary epidemiological data on
the prevalence of carotid atherosclerosis in the general population. The
aim was to determine the prevalence of and risk factors associated with ca-
rotid artery atherosclerosis among 65-year-old men.
Methods: This was a population-based screening study. All 65-year-
old men in the County of Uppsala, Sweden, who attended screening for
abdominal aortic aneurysm (AAA) 2007e2009, were invited for duplex
scanning of the carotid arteries.
Results: Of 4801 men invited, 4657 (97%) accepted. Carotid plaques
(>2  6 mm) were observed in 1169 (25%) men, 94 (2.0%) had carotid ste-
noses (50e99%), and 15 (0.3%) had occluded carotid arteries. In a multivar-
iate logistic regression model, smoking (OR 1.7, 95% CI 1.5e1.9),
hypertension (1.5, 95% CI 1.3e1.7), diabetes mellitus (1.2, 95% CI
1.0e1.5), and coronary artery disease (1.5, 95% CI 1.3e1.8) were associ-
ated with prevalence of carotid atherosclerosis (plaque and/or stenosis).
The use of antiplatelet agents and statins in participants with a carotid pla-
que was 20% and 29%, respectively. The corresponding ﬁgures in partici-
pants with a stenosis were 42% and 41%.
Conclusions: This study offers contemporary data on the prevalence
of carotid atherosclerosis in a population-based cohort of 65-year-old
men. Most of those at risk had no other clinical manifestation of atheroscle-
rosis, and therefore had no secondary prevention.
Treatment Decisions for Descending Thoracic Aneurysm: Preferences
for Thoracic Endovascular Aneurysm Repair or Surveillance in a
Discrete Choice Experiment
Rudarakanchana N., Reeves B.C., Bicknell C.D., Heatley F.M.,
Cheshire N.J., Powell J.T. Eur J Vasc Endovasc Surg 2014;48:13-22.
Objective: To investigate and rank factors that inﬂuence endovascular
treatment decisions by specialists for patients with descending thoracic
aortic aneurysm (dTAA).
Methods: Specialists completed a diagrammatic survey describing un-
certainty about the beneﬁt of thoracic endovascular aneurysm repair
(TEVAR) for dTAA with respect to age, sex, and aneurysm diameter. Sub-
sequently, a detailed discrete choice experiment was designed. Specialists
were recruited and asked to indicate treatment their preference (TEVAR
or surveillance) in 25 hypothetical cases of dTAA, with variable patient at-
tributes: age, sex, American Society of Anesthesiologists (ASA) grade, aneu-
rysm diameter, adequate landing zone distal to left subclavian artery (LSA),
and length of aortic coverage. Data were analysed using multiple logistic
regression.
Results: The diagrammatic survey, based on 50 respondents, showed
that uncertainty about the beneﬁts of TEVAR was greatest for patients aged
80e85 years (up to 47% of respondents were “unsure”) and that uncer-
tainty increased with increasing aneurysm diameter (for an 80-year-old
man, 7% were unsure at 5.5 cm and 33% were unsure at 7.0 cm). Sev-
enty-one specialists (mainly from Europe and North America, 86% vascular
surgeons and 98% working in units offering TEVAR) completed the discrete
choice experiment. Preference for TEVAR increased greatly with enlarging
diameter: adjusted odds ratios (OR) >5.5e6.0 cm = 15.8 (95% conﬁdence
interval [CI] 9.83e25.40); >6.0e6.5 cm = 393.0 (95% CI
202.00e766.00); >6.5e7.0 cm = 1829.0 (95% CI 400.00e4,181.00).
TEVAR was less likely to be preferred in patients older than 75 years
(>75e80 years OR 0.32, 95% CI 0.21e0.49; >80e85 years = 0.18, 95%
CI 0.11e0.28); in women (OR 0.52, 95% CI 0.37e0.74); in patients clas-
siﬁed as ASA grade 4 (OR 0.44, 95% CI 0.36e0.57); and in patients with
aorta coverage >25 cm (OR 0.48, 95% CI 0.32e0.74). The proximal land-
ing zone did not inﬂuence preference.
Conclusion: Specialists' preferences for endovascular repair of degen-
erative dTAA vary widely, and demonstrate clinical uncertainty, especially in
octogenarians, and a reluctance to offer TEVAR to women. Aneurysmdiameter dominates treatment preferences, but patient ﬁtness and length
of aortic coverage (>25 cm) also were inﬂuential, although the landing
zone distal to LSA was not.
Spontaneous Delayed Sealing in Selected Patients with a Primary
Type-Ia Endoleak After Endovascular Aneurysm Repair
Bastos Gonçalves F., Verhagen H.J.M., Vasanthananthan K.,
Zandvoort H.J.A., Moll F.L., van Herwaarden J.A. Eur J Vasc Endovasc
Surg 2014;48:53-9.
Objective: Direct additional therapy is advised for type-Ia endoleaks
detected on completion angiography after endovascular aneurysm repair
(EVAR). Additional intraoperative endovascular procedures are, however,
often challenging or not possible, and direct open conversion is unattractive.
The results of a selective, conservative strategy for patients with primary
type-Ia endoleak has been analysed.
Methods: This was a retrospective, single-centre study (UMC,
Utrecht, NL). From 2004 to 2008, all patients with a primary type-Ia endo-
leak and suitable anatomy for EVAR, stentgraft oversizing $15%, and
optimal deployment were included. Complications during follow-up were
studied and all sequential CTA scans were reviewed. These were compared
with the remaining patients, treated during the same period.
Results: Fifteen patients were included (14 male, median age 77,
range 67e85) with a median aneurysm diameter of 60 mm (48e80),
an aneurysm neck diameter of 26 mm (21e32), a neck length of 29
mm (11e39), and infrarenal angulation of 49 (31e90). One patient suf-
fered rupture 2 days after EVAR e leading to the only AAA-related death.
Eight of the 15 type-Ia endoleaks disappeared spontaneously on the ﬁrst
postoperative CTA, obtained within 1 week of EVAR. On the second
postoperative CTA, obtained a median of 5 months (1e12) after
EVAR, all remaining endoleaks had sealed. One recurrence occurred at
4.85 years. During a median follow-up of 3.3 years, there were ﬁve sec-
ondary interventions. Compared with controls, there were more second-
ary (or recurrent) type-1a endoleaks (13% vs. 4%), endograft migrations
(13% vs. 3%), sac growths (33% vs. 16%), and secondary interventions
(33% vs. 23%). None of these differences however, were statistically
signiﬁcant.
Conclusions: All but one of the primary type-Ia endoleaks sealed
spontaneously. Until sealing, the risk of rupture persisted, but subsequently
only one recurrence of type-Ia endoleak was seen. In selected patients, a
conservative approach for primary type-Ia endoleaks may be justiﬁed.
Healthcare Quality Indicators of Peripheral Artery Disease Based on
Systematic Reviews
Bellmunt S., Roqué M., Osorio D., Pardo H., Escudero J.-R., Bonﬁll X. Eur
J Vasc Endovasc Surg 2014;48:60-9.
Objectives: Peripheral artery disease (PAD) is a major health problem
whose clinical management includes multiple options regarding risk factor
control, diagnosis, and medical and surgical treatment. The aim was to
generate indicators based on systematic reviews to evaluate the quality of
healthcare provided in PAD.
Methods: Electronic searches were run for systematic reviews in The
Cochrane Library (Issue 6, 2011), MEDLINE, EMBASE, and other data-
bases (up to June 2011). Conclusive systematic reviews of high methodo-
logical quality were selected to formulate clinical recommendations.
Indicators were derived from clinical recommendations with moderate to
very high strength of evidence as assessed by the GRADE system.
Results: From 1,804 reviews initially identiﬁed, 29 conclusive and
high-quality systematic reviews were selected and nine clinical recommenda-
tions were formulated with a moderate to very high strength of recommen-
dation. Six indicators were ﬁnally generated: four on pharmacological
interventions, antiplatelet agents, naftidrofuryl, cilostazol, and statins; and
two lifestyle interventions, exercise and tobacco cessation. No indicators
were derived for diagnostic tests or surgical techniques. Most indicators tar-
geted patients with intermittent claudication.267
